CVS Healthの空売り状況は、投資家がCVS Healthの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

CVS Health (NYSE:CVS) 株価情報, 空売り情報

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

CVS HEALTH ORD

News

Guidance

CVS Executive Says Company Is Not Providing A Formal Outlook For 2024 At This Stage

CVS Executive Says Healthcare Benefits Segment Continues to Underperform But Remain Valuable; Says Challenges Associated With Covid-19 Pandemic, Higher Acuity Levels, And Underestimation Of Medical Cost Exacerbated Utilization Pressures

U.S. stocks could witness a strong opening on Wednesday after former President Donald Trump <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">emerged victorious</a> after a long-drawn battle with Joe Biden and Kamala Harris.
With Trump returning as the U.S. President, futures of all three major indices were strongly in the green on Wednesday, pointing to upbeat sentiment on Wall Street.
The Associated Press called a Republican win in three out of seven key swing states – North Carolina, Pennsylvania, Georgia, and Wisconsin. While Michigan and Arizona are still in play, trends lean toward Trump here, too.
Shares of Trump's social media company, Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>), and his billionaire ally, Elon Musk's Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), surged in premarket trading on Wednesday.
While Trump Media shares were up over 33% in premarket trading, Tesla shares were up over 14% at the time of writing.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Performance (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>1.74%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>2.27%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>2.87%</td>
</tr>
<tr>
<td>R2K</td>
<td>6.16%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) gained 2.33% to $590.23 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.82% to $501.15, according to <a href="https://benzinga.grsm.io/lxquj26b2sag">Benzinga Pro data</a>.
Cues From Last Session:
All three major indices ended the Tuesday session on a positive note, with the tech-heavy Nasdaq Composite surging the most.
Oil prices eased at the prospect of a Trump win resulting in a stronger U.S. dollar.
Treasury yields <a href="https://www.benzinga.com/news/24/11/41765345/treasury-yields-pop-on-trump-victory-chances-10-year-benchmark-reaches-4-month-high">popped at the prospect</a> of a Trump victory. The benchmark 10-year yield rose to levels last seen in July.
According to the CRFB's central estimate, Trump would increase the national debt by $7.75 trillion between 2026 and 2035, leading the government to issue more bonds to fund the deficit.&nbsp;
All sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, industrials, and utilities stocks recording the biggest gains on Tuesday.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.43%</td>
<td>18,439.17</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.23%</td>
<td>5,782.76</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.02%</td>
<td>42,221.88</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.88%</td>
<td>2,260.84</td>
</tr>
</tbody>
</table>
</figure>
It's not just the equities that surged – top cryptocurrency Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also surged to a new all-time high of $75,000 – at the time of writing, Bitcoin prices cooled a little to trade at $73,737, up more than 7% in the last 24 hours.
Insights From Analysts:
Veteran investor Mark Mobius, chairman of Mobius Emerging Opportunities Fund, <a href="https://www.cnbc.com/">told</a> CNBC that a Trump victory would be good for the U.S. economy.
"It looks like a Trump presidential win but also a win for Republicans in House and Senate. If that happens, you're going to see the U.S. economy really taking off," he said.
Ryan Detrick, chief market strategist at Carson Group, believes that the stage is now set for U.S. equities to rally through the year-end.
"Once we kind of get through the election uncertainty… we do think that could potentially be the springboard to a potential another strong November," Detrick told CNBC in an interview.
"This economy is still strong. This is still a bull market."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Here&#39;s my full interview with <a href="https://twitter.com/ScottWapnerCNBC?ref_src=twsrc%5Etfw">@ScottWapnerCNBC</a> on <a href="https://twitter.com/CNBCClosingBell?ref_src=twsrc%5Etfw">@CNBCClosingBell</a> today. &#x2A; Why a rally is likely once we get the election out of the way &#x2A; The Fed could be what upsets markets this week &#x2A; Tech is pricey, but there are some cheap areas for investors <a href="https://t.co/OHRImYEaCl">https://t.co/OHRImYEaCl</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1853935196065730946?ref_src=twsrc%5Etfw">November 5, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Stephen Dainton, President of Barclays Bank PLC and Head of Investment Bank Management, told <a href="https://www.wsj.com/livecoverage/stock-market-today-fed-meeting-dow-nasdaq-sp500-live-11-06-2024/card/-full-on-trump-trade-investors-pile-into-stocks-dump-treasurys-ODshDaYnFSIb7kB2a2Ir?mod=lctimeline_finance">the</a> Wall Street Journal that the markets had already decided that Trump would win.
&#8220;The markets are now trading full-on Trump trade."
Echoing Detrick&#8217;s bull run thesis, WisdomTree and Wharton School economist&nbsp;Jeremy Siegel&nbsp;said the equity surge could continue.
&#8220;In the near term, stock markets seem poised for further gains, bolstered by resilient earnings and steady economic fundamentals, while bond markets will likely grapple with higher yields and volatility ahead,&#8221; he said.
&#8220;The bull market in stocks looks set to continue, while bonds face a rougher road.&#8221;
On the economic data front, the trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August.
The ISM services PMI rose to 56 in October, recording the highest reading since Aug. 2022.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Wednesday's economic calendar is light, with only S&amp;P scheduled to release the final U.S. services purchasing manager&#8217;s index (PMI) at 9:45 a.m. ET.
Stocks In Focus:
<ul>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares popped over 37% in premarket trading on Wednesday.</li>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares surged over 15%. CEO Elon Musk has been a vocal Trump supporter and has also advocated for a "Department of Government Efficiency," or "DOGE."</li>
<li>Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) shares surged over 13% after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) prices topped $75,000 for the first time.</li>
<li>Private prison company Geo Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEO#NYSE">GEO</a>) shares gained over 24% during premarket hours.</li>
<li>Stocks of the biggest U.S. lenders, JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), The Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>), and Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) gained between 7% and 9% in premarket hours.</li>
<li>Investors are awaiting earnings results from CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Johnson Controls International Plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>), and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures eased in the early New York session, falling by 1.25% as Trump's return to the White House has led to a stronger U.S. dollar.
The 10-year Treasury note yield surged to 4.467%.
Major Asian markets ended Wednesday on a mixed note, while European stocks showed strength in early trading.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Donald Trump Defeats Kamala Harris To Win 2024 Election</a></li>
</ul>
Photo courtesy: Wikimedia

Earnings

Equities

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Movers

Trading Ideas

$BTC

COIN

QCOM

TSLA

Dow, Nasdaq Futures Race Higher As Trump Wins White House: DJT, Tesla Shares Surge — Veteran Investor Predicts US Economy Could 'Take Off'

WIIM

CVS shares are trading higher following a Q3 revenue beat.

Earnings Beats

Earnings Misses

CVS Health Q3 2024 Adj. EPS $1.09 Misses $1.53 Estimate, Sales $95.428B Beat $92.747B Estimate

The CNN Money Fear and Greed index showed an improvement in the overall market sentiment, but the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Monday, with the Dow Jones index gaining more than 400 points as investors awaited the results of the U.S. presidential election. The Federal Reserve is also scheduled to announce its November rate decision on Thursday.
On the economic data front, the trade deficit in the U.S. increased to $84.4 billion in September, recording the highest level since April 2022, and above market estimates of a $84.1 billion gap, versus a revised $70.8 billion gap in August. The ISM services PMI rose to 56 in October, recording the highest reading since Aug. 2022.
Yum! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>) posted downbeat results for its third quarter. Shares of Vimeo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMEO#NASDAQ">VMEO</a>) jumped around 45% on Tuesday after the company reported better-than-expected third-quarter financial results and issued fourth-quarter sales guidance above estimates.
All sectors on the S&amp;P 500 closed on a positive note, with consumer discretionary, industrials, and utilities stocks recording the biggest gains on Tuesday.
The Dow Jones closed higher by around 427 points to 42,221.88 on Tuesday. The S&amp;P 500 gained 1.23% to 5,782.76, while the Nasdaq Composite jumped 1.43% to close at 18,439.17 during Tuesday's session.
Investors are awaiting earnings results from CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>), and Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 43.5, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 41.2.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

VMEO

Dow, Nasdaq Jump Over 1% Ahead Of Election Results: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone

With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) to report quarterly earnings at $1.53 per share on revenue of $92.75 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. CVS Health shares rose 0.7% to $55.70 in after-hours trading.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported better-than-expected third-quarter financial results and issued FY24 guidance above estimates. The company reported quarterly earnings of 83 cents per share which beat the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million. Globus Medical shares surged 10.3% to $83.35 in the after-hours trading session.</li>
<li>Analysts are expecting Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) to post quarterly earnings at $1.2 per share on revenue of $7.17 billion. The company will release earnings before the markets open. Johnson Controls International shares rose 2.3% to $76.55 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) lowered its financial outlook. The company expects to report first-quarter revenue of $5.9 billion to $6 billion, down from its previous guidance range of $6 billion to $7 billion. The company anticipates adjusted earnings of 75 cents to 76 cents per share, versus its previous guidance of 67 cents to 83 cents per share. Super Micro Computer shares dipped 16% to $23.28 in the after-hours trading session.</li>
<li>Analysts expect Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) to report quarterly earnings at $2.56 per share on revenue of $9.9 billion after the closing bell. QUALCOMM shares gained 0.2% to $166.19 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

GMED

SMCI

CVS Health, Johnson Controls And 3 Stocks To Watch Heading Into Wednesday

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALLK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.00</td>
<td>$44.7K</td>
<td>552</td>
<td>2.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$19.00</td>
<td>$57.0K</td>
<td>804</td>
<td>1.7K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$45.00</td>
<td>$40.6K</td>
<td>292</td>
<td>866</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$210.00</td>
<td>$32.3K</td>
<td>1.6K</td>
<td>719</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$120.00</td>
<td>$142.8K</td>
<td>2.9K</td>
<td>504</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$800.00</td>
<td>$26.5K</td>
<td>379</td>
<td>274</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$50.00</td>
<td>$232.6K</td>
<td>1.5K</td>
<td>235</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$55.0K</td>
<td>368</td>
<td>155</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$285.00</td>
<td>$34.5K</td>
<td>428</td>
<td>155</td>
</tr>
<tr>
<td>AMGN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$365.00</td>
<td>$53.5K</td>
<td>215</td>
<td>108</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding ALLK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>), we observe a call option sweep with bullish sentiment. It expires in 45 day(s) on December 20, 2024. Parties traded 819 contract(s) at a $1.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $44.7K, with a price of $55.0 per contract. There were 552 open contracts at this strike prior to today, and today 2319 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a put option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 300 contract(s) at a $19.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $57.0K, with a price of $190.0 per contract. There were 804 open contracts at this strike prior to today, and today 1754 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 58 contract(s) at a $45.00 strike. This particular call needed to be split into 23 different trades to become filled. The total cost received by the writing party (or parties) was $40.6K, with a price of $700.0 per contract. There were 292 open contracts at this strike prior to today, and today 866 contract(s) were bought and sold. 
• Regarding ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we observe a call option sweep with bearish sentiment. It expires in 73 day(s) on January 17, 2025. Parties traded 719 contract(s) at a $210.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $32.3K, with a price of $45.0 per contract. There were 1601 open contracts at this strike prior to today, and today 719 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be bearish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 340 contract(s) at a $120.00 strike. This particular call needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $142.8K, with a price of $420.0 per contract. There were 2969 open contracts at this strike prior to today, and today 504 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bullish sentiment. It expires in 10 day(s) on November 15, 2024. Parties traded 15 contract(s) at a $800.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $26.5K, with a price of $1773.0 per contract. There were 379 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• Regarding CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we observe a call option sweep with bullish sentiment. It expires in 437 day(s) on January 16, 2026. Parties traded 227 contract(s) at a $50.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $232.6K, with a price of $1025.0 per contract. There were 1525 open contracts at this strike prior to today, and today 235 contract(s) were bought and sold. 
• Regarding MRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), we observe a call option sweep with bullish sentiment. It expires in 163 day(s) on April 17, 2025. Parties traded 77 contract(s) at a $65.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $55.0K, with a price of $715.0 per contract. There were 368 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 10 day(s) on November 15, 2024. This event was a transfer of 75 contract(s) at a $285.00 strike. The total cost received by the writing party (or parties) was $34.5K, with a price of $460.0 per contract. There were 428 open contracts at this strike prior to today, and today 155 contract(s) were bought and sold. 
• For AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we notice a call option sweep that happens to be bullish, expiring in 73 day(s) on January 17, 2025. This event was a transfer of 104 contract(s) at a $365.00 strike. This particular call needed to be split into 28 different trades to become filled. The total cost received by the writing party (or parties) was $53.5K, with a price of $515.0 per contract. There were 215 open contracts at this strike prior to today, and today 108 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ALLK

AMGN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MRNA

10 Health Care Stocks Whale Activity In Today's Session

As CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) prepares to announce its third-quarter earnings Wednesday morning, investors are keenly aware of the challenges and adjustments the company <a href="https://www.benzinga.com/news/earnings/24/08/40220306/cvs-health-reports-mixed-q2-earnings-lowers-2024-outlook-reshuffles-segment-management">has faced in recent months</a>. 
Following a mixed performance in its <a href="https://www.benzinga.com/quote/CVS/earnings">second-quarter results</a>, which included a significant reduction in annual profit guidance, CVS's stock has experienced volatility, reflecting market concerns about its future prospects.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41714263/nxp-semiconductors-prepares-for-earnings-with-new-ai-tools-but-what-do-the-charts-reveal">NXP Semiconductors Prepares For Earnings With New AI Tools: But What Do The Charts Reveal?</a>
What To Know: In the second quarter, CVS Health reported: 
<ul>
<li>Revenues of $91.23 billion, falling short of the consensus estimate of $91.51 billion. T</li>
<li>Total revenues grew by 2.6% — fueled by the Health Care Benefits and Pharmacy &amp; Consumer Wellness segments.</li>
<li>Adjusted earnings per share (EPS) of $1.83 also represented a decrease from $2.21 in the previous year, although it did surpass the consensus forecast of $1.73. The decline in EPS stems from operational pressures in the Health Care Benefits segment, exacerbated by unfavorable Medicare Advantage star ratings impacting the 2024 payment year.</li>
<li>Adjusted operating income reflected a more significant downturn, decreasing by 16.4% to $3.74 billion. This decline highlighted the ongoing challenges CVS is facing, particularly in managing costs and improving operational efficiency.</li>
<li>The company&#8217;s Health Services segment reported a troubling 8.8% decrease in revenues to $42.17 billion, largely due to an 18.3% drop in pharmacy claims processed. This downturn raises questions about CVS&#8217;s ability to compete in an increasingly digital landscape, where online pharmacy services are becoming more prevalent.</li>
</ul>
What Else: In response to these challenges, CVS announced immediate leadership changes, with CEO Karen Lynch taking direct control of the Health Care Benefits segment, while CFO Tom Cowhey will oversee daily operations alongside her. Such moves signal CVS&#8217;s commitment to reorienting its strategy in light of recent performance.
Guidance for the upcoming quarter and beyond has been notably conservative. CVS has revised its adjusted EPS forecast down to between $6.40 and $6.65, significantly lower than the previous estimate of at least $7.00 and below the consensus of $6.98. 
Additionally, the company adjusted its full-year 2024 cash flow from operations guidance to approximately $9.0 billion, down from an earlier estimate of at least $10.5 billion. This revision reflects ongoing pressures in the Health Care Benefits segment, prompting concerns about future profitability. Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41715442/trump-media-stock-volatile-on-election-eve-as-polls-betting-markets-predict-tight-white-ho">Trump Media Stock Volatile On Election Eve As Polls, Betting Markets Predict Tight White House Race</a>
The Big Picture: For the full year, CVS forecasts revenues between $369 billion and $372 billion, slightly above the consensus of $368.876 billion, while the adjusted operating income is now expected to fall between $13.75 billion and $14.15 billion, a reduction from previous guidance of at least $14.75 billion.
Furthermore, the anticipated medical benefits ratio has been adjusted to a range of 90.6% to 90.8%, up from the earlier expectation of approximately 89.8%.
As CVS Health approaches its third-quarter earnings announcement, market analysts will be closely monitoring the company&#8217;s ability to navigate these challenges and deliver results that align with its revised guidance. 
Investors will look for signs of improvement in the Health Services segment and any indications that leadership changes will positively impact operational performance moving forward.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41715076/oil-prices-spike-by-over-3-as-opec-delays-production-increases-ahead-of-us-electi">Oil Prices Spike By Over 3% As OPEC+ Delays Production Increases Ahead Of US Elections: 5 Energy ETFs To Watch Monday</a></li>
</ul>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CVS has a 52-week high of $83.25 and a 52-week low of $52.77.
Image: Shutterstock

CVS Health Q3 Earnings Preview: Can The Company Overcome Recent Challenges?

Wells Fargo analyst Stephen Baxter maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Equal-Weight and lowers the price target from $61 to $60.

Price Target

Analyst Ratings

Wells Fargo Maintains Equal-Weight on CVS Health, Lowers Price Target to $60

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has risen 5.1% since its last report. The company recently reported that it has 20.80 million shares sold short, which is 1.65% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730135713_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 8.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into CVS Health's Recent Short Interest

Mizuho analyst Ann Hynes maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Outperform and lowers the price target from $73 to $66.

Mizuho Maintains Outperform on CVS Health, Lowers Price Target to $66

Investors with a lot of money to spend have taken a bearish stance on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CVS, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 17 uncommon options trades for CVS Health.
This isn't normal.
The overall sentiment of these big-money traders is split between 41% bullish and 47%, bearish.
Out of all of the special options we uncovered, 6 are puts, for a total amount of $401,867, and 11 are calls, for a total amount of $429,972.
<h3>Predicted Price Range</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $75.0 for CVS Health during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for CVS Health's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CVS Health's whale activity within a strike price range from $50.0 to $75.0 in the last 30 days. 
<h3>CVS Health Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729715429_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$13.2</td>
<td>$70.00</td>
<td>$132.0K</td>
<td>4.0K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$18.2</td>
<td>$18.2</td>
<td>$18.2</td>
<td>$75.00</td>
<td>$127.4K</td>
<td>1.8K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$3.05</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$60.00</td>
<td>$64.0K</td>
<td>1.1K</td>
<td style="text-align: right;">224</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$5.4</td>
<td>$5.3</td>
<td>$5.4</td>
<td>$70.00</td>
<td>$54.0K</td>
<td>182</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.49</td>
<td>$2.44</td>
<td>$2.48</td>
<td>$57.50</td>
<td>$49.6K</td>
<td>4.1K</td>
<td style="text-align: right;">231</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>With a trading volume of 9,648,772, the price of CVS is down by -0.11%, reaching $56.79.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 14 days from now.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $74.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Evercore ISI Group continues to hold a Outperform rating for CVS Health, targeting a price of $75. 
&#x2A; An analyst from Truist Securities persists with their Buy rating on CVS Health, maintaining a target price of $76. 
&#x2A; An analyst from Barclays has elevated its stance to Overweight, setting a new price target at $82. 
&#x2A; An analyst from Barclays persists with their Overweight rating on CVS Health, maintaining a target price of $75. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $62. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CVS Health with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

What the Options Market Tells Us About CVS Health

In the last three months, 15 analysts have published ratings on CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), offering a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $68.0, a high estimate of $85.00, and a low estimate of $61.00. Witnessing a positive shift, the current average has risen by 6.25% from the previous average price target of $64.00.
<img src="https://www.benzinga.com/files/images/story/2024/1729702860_0_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CVS Health's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Charles Ryhee</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$63.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$63.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CVS Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into CVS Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on CVS Health analyst ratings.</a>
<h2>Delving into CVS Health's Background</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
<h3>Financial Insights: CVS Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining CVS Health's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.6% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: CVS Health's net margin is impressive, surpassing industry averages. With a net margin of 1.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CVS Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 2.38%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): CVS Health's ROA excels beyond industry benchmarks, reaching 0.7%. This signifies efficient management of assets and strong financial health.
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.12.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where CVS Health Stands With Analysts

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $82 to $75.

Barclays Maintains Overweight on CVS Health, Lowers Price Target to $75

Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) announced on Tuesday that it will begin offering Pharmacy Delivery services for both new prescriptions and medication refills, intensifying competition in <a href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo">the pharmacy retail space.</a>
The Details: Walmart is <a href="https://www.benzinga.com/pressreleases/24/10/b41449460/accelerating-convenience-walmart-launches-nationwide-same-day-pharmacy-delivery-helping-customers-">rolling out</a> Pharmacy Delivery in six states and expects the new service to expand to 49 states by the end of January 2025. Walmart+ members will receive free delivery on Pharmacy Delivery, and non-Walmart+ members will pay the standard delivery charge of $9.95. 
"​​Our extensive footprint across the nation combined with our deep expertise in pharmacy uniquely positions us to make a profound impact in the communities we serve,&#8221; said Kevin Host, senior vice president of Pharmacy at Walmart U.S.
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431993/amd-to-benefit-from-ai-competitive-arms-race-goldman-sachs"> AMD To Benefit From AI &#8216;Competitive Arms Race&#8217;: Goldman Sachs</a>
Why It Matters: Walmart's Pharmacy Delivery is another blow to struggling pharmacy retailers CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Walgreens Boots Alliance, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) who offer comparable delivery services. The retail giant's move into prescription delivery could lead to market share losses for CVS and Walgreens who already compete with Amazon.com, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/news/large-cap/24/10/41270285/amazon-pharmacy-to-double-service-areas-offer-same-day-medication-delivery">same-day prescription delivery</a> in some areas. Amazon has plans to expand its pharmacy delivery to 20 more U.S. cities by 2025.
CVS and Walgreens have said <a href="https://www.benzinga.com/news/earnings/24/10/41405992/elevance-cvs-unitedhealth-struggle-with-rising-medical-costs-after-covid-19-medicaid-policy-ends">they are struggling</a> with falling reimbursement rates for prescription drugs. Both retail chains have shuttered store locations and announced cost-cutting measures as part of corporate turnaround strategies. 
The stores may face increased pressure on profit margins and staffing needs due to increased competition from Walmart. Both retailers have already reduced pharmacy hours in response to staffing challenges, which have been partly driven by the need to support delivery services.&nbsp;
WMT, CVS, WBA, AMZN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Walmart shares are up 0.67% at $81.35, CVS shares are down 1.74% at $57.16, Walgreens shares are down 4.64% at $9.96 and Amazon shares are up 0.42% at $189.87 at the time of publication Tuesday.
Read Also:&nbsp;
<ul>
<li>&nbsp;<a href="https://www.benzinga.com/news/24/10/41418987/nuclear-energy-stocks-are-hot-heres-a-list-of-tickers-to-watch">Nuclear Energy Stocks Are Hot: Here&#8217;s A List Of Tickers To Watch</a></li>
</ul>
Photo: Jeff Bukowski/Shutterstock.com

Health Care

General

AMZN

Walmart Launches Same-Day Pharmacy Delivery, Upping Competition For CVS, Walgreens

Shares of CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) were under pressure in early Monday trading after the company preannounced <a href="https://www.benzinga.com/news/24/10/41401771/cvs-health-cuts-outlook-joins-american-express-and-other-big-stocks-moving-lower-in-fridays-pre-mark">an earnings miss for the third quarter</a>.
The company reported its results amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst takeaways.
Piper Sandler On CVS Health
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/613f2550b4035700018da9d8/jessica-tassan">Analyst Jessica Tassan</a> maintained an Overweight rating and price target of $72.
CVS Health preannounced a significant MLR (medical loss ratio) and earnings miss for the third quarter and withdrew its full-year guidance, Tassan said in a note. "During 3Q24, CVS recorded $1.1B of premium deficiency reserves primarily related to the Medicare and Individual Exchange businesses within HCB (health care benefits)," she wrote.
While rates, risk adjustment and the IRA are exerting pressure on Medicare Advantage, CVS Health has some "self-induced" issues in the Healthcare Benefits (HCB) segment, which should begin to resolve in 2025, the analyst stated. David Joyner has taken over CEO, effective immediately, and could deliver a "multi-year earnings recovery," she added.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Truist Securities On CVS Health
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c2a8e2b85e930001ba538c/david-macdonald">Analyst David MacDonald</a> reiterated a Buy rating and price target of $76.
CVS Health preannounced its third-quarter adjusted earnings at $1.05-$1.10 per share, significantly below consensus of $1.69 per share, MacDonald said. The results include a charge of around $1.1 billion to record premium deficiency reserves primarily related to the Medicare and Individual Exchange books, which translates to an adjusted earnings headwind of 63 cents per share, he added.
Management no longer believes its prior guidance for 2024 is appropriate, "given continued elevated utilization pressure," the analyst stated. CEO Karen Lynch stepped down and was replaced by industry veteran Joyner, who brings "a wealth of experience in pharmacy services," he further wrote.
CVS Price Action: Shares of CVS Health were down 1.17% to $58.98 at the time of publication on Monday.
Read Next:
<ul>
<li> <a href="https://www.benzinga.com/news/large-cap/24/10/41418999/nio-asml-and-cvs-health-are-among-top-10-large-cap-losers-last-week-oct-14-18-are-the-others-in-yo">NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Wikimedia Commons

Analyst Color

Reiteration

CVS Health Preannounces Large Earnings Miss, But Analysts Stay Bullish On Long-Term Recovery

In a significant development in the health insurance industry, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has reinitiated discussions to merge with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), potentially creating a giant in the sector.
Talks, previously stalled over pricing disagreements, have resumed with a focus on a transformative consolidation that could reshape market dynamics.
According to a <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> report on Friday, the early talks about the merger would significantly expand Cigna&#8217;s footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana&#8217;s strong Medicare segment.
Also: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>
Last year, both <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today" rel="noreferrer noopener">companies faced challenges</a> as they navigated federal pressures to reduce Medicare costs, severely impacting Humana&#8217;s market performance and valuation.
These resumed talks hint at a possible major realignment aiming to fortify their positions against competitors like UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and&nbsp;CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The merger discussions are still in the nascent stages, with no decisions made. Both companies declined to comment on the ongoing negotiations.
A potential deal, estimated to be among the top five health insurance mergers, reflects a strategic shift in the industry focused on consolidation amid rising healthcare costs and stringent regulatory environments.
This deal could not only stabilize Humana&#8217;s declining Medicare enrollments but also enhance Cigna&#8217;s capabilities in managing more comprehensive healthcare plans.
Furthermore, a merger could ease the competitive pressure from the rapidly growing sectors of the industry, providing a robust challenge to established giants.
Humana&#8217;s stock value sharply declined due to lower-than-expected government reimbursements and increased demand for medical services. The merger is, therefore, potentially crucial for recovery and growth.
Price Action: CI stock is down 4.18% at $321.94, and HUM stock is up 0.88% at $269.50 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" target="_blank" rel="noreferrer noopener">After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment</a>.</li>
</ul>
Photo via Shutterstock

Large Cap

Rumors

Media

Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) stock lost 16.35% last week as U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41385461" target="_blank" rel="noreferrer noopener">fell after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) stock dipped 15.58%, probably due to continued weakness following weak guidance from ASML.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares were down 14.38%. The company will report <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">third-quarter results on October 25</a>.</li>
<li>Elevance Health shares dipped 14.17% after analysts cut forecasts <a href="https://www.benzinga.com//node/41405601" target="_blank" rel="noreferrer noopener">following third-quarter earnings</a>.</li>
<li>ASML Holding N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shares tumbled 13.97% after the company accidentally released earnings a day ahead of schedule and <a href="https://www.benzinga.com//node/41358875" target="_blank" rel="noreferrer noopener">cut its 2025 sales forecast</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) stock fell 13.91%, as did U.S.-listed Chinese stocks <a href="https://www.benzinga.com//node/41316058" target="_blank" rel="noreferrer noopener">after China&#8217;s September exports</a> missed estimates. China stimulus uncertainty has also weighed on stocks recently.</li>
<li>Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares were down 12.24%, probably in sympathy with Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), which reported third-quarter earnings miss and issued soft FY24 guidance.</li>
<li>Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) stock dived 12.12%, probably in sympathy with Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>), which reported better-than-expected <a href="https://www.benzinga.com//node/41377745" target="_blank" rel="noreferrer noopener">earnings and issued strong guidance</a>.</li>
<li>Erie Indemnity Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERIE#NASDAQ">ERIE</a>) fell 9.92% last week after Spruce Point Management <a href="https://www.sprucepointcap.com/research/erie-indemnity-company" target="_blank" rel="noreferrer noopener">issued a short-sell report</a> on the stock. The company was under pressure due to Category 5 Hurricane Milton.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) stock fell 9.44% last week after the company <a href="https://www.benzinga.com//node/41399396" target="_blank" rel="noreferrer noopener">cut its Q3 outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

ASML

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

ERIE

KLAC

LRCX

Citigourp Global Markets 2% Protected Notes Linked To The Djia

NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?

U.S. stocks traded mostly higher toward the end of trading, with the Nasdaq Composite gaining over 100 points on Friday.
The Dow traded up 0.04% to 43,258.31 while the NASDAQ rose 0.67% to 18,496.61. The S&amp;P 500 also rose, gaining, 0.40% to 5,865.01.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41377157/top-3-risk-off-stocks-which-could-rescue-your-portfolio-this-quarter">Top 3 Risk Off Stocks Which Could Rescue Your Portfolio This Quarter</a>
Leading and Lagging Sectors Communication services shares jumped by 1% on Friday.
In trading on Friday, energy shares fell by 0.5%.
Top Headline
Schlumberger N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) reported mixed third-quarter results.
Revenue grew 10.2% year over year to $9.159 billion, missing the consensus of $9.25 billion. Adjusted EPS increased 14% to 89 cents, above the consensus of 88 cents.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>United States Cellular Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) shares shot up 7% to $62.56 after the company announced the sale of a portion of its retained spectrum licenses to Verizon for $1 billion.</li>
<li>Shares of Bright Minds Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) got a boost, surging 159% to $56.25. The company announced a $35 million non-brokered private placement.</li>
<li>SOBR Safe, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) shares were also up, gaining 27% to $10.10 after the company announced it filed a form RW and will not pursue a public offering at this time.</li>
</ul>
Equities Trading DOWN
<ul>
<li>MGP Ingredients, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGPI#NASDAQ">MGPI</a>) shares dropped 25% to $60.96 after the company issued soft preliminary guidance and lowered its 2024 financial outlook.</li>
<li>Shares of Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) were down 15% to $0.4917. On Thursday, Canaccord Genuity downgraded the stock from Buy to Hold and cut its price target from $1.85 to $0.70.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) was down, falling 6% to $59.83 after the company cut its third-quarter outlook.</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $69.62 while gold traded up 0.9% at $2,731.20.
Silver traded up 4.9% to $33.325 on Friday, while copper rose 1.5% to $4.3880.
Euro zone
European shares closed mostly higher today. The eurozone's STOXX 600 rose 0.21%, Germany's DAX rose 0.38% and France's CAC 40 climbed 0.39%. Spain's IBEX 35 Index rose 0.17%, while London's FTSE 100 fell 0.32%.
Construction output in the Eurozone fell by 2.5% year-over-year in August compared to a revised 2.3% decline in the previous month. The current account surplus in the Eurozone increased to €35.2 billion in August from €26.8 billion in the year-ago period.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index climbing 3.61%, China's Shanghai Composite Index gaining 2.91% and India's BSE Sensex gaining 0.27%.
Economics
<ul>
<li>U.S. housing starts fell by 0.5% from the previous month to an annualized rate of 1.354 million units in September.</li>
<li>Building permits declined by 2.9% to an annual rate of 1.428 million in September.</li>
<li>The total number of active U.S. oil rigs rose by one to 482 rigs this week, Baker Hughes Inc reported.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>

DRUG

LILM

MGPI

SOBR

Nasdaq Surges Over 100 Points; Schlumberger Reports Mixed Q3 Result

Earnings Snapshot: CVS Health beats top-line estimates in Q3

CVS Health in charts: Health Care Benefits segment revenues hits $33B, +25.5% Y/Y

CVS Health gains after Q3 beat; adds former UnitedHealth exec. to run Aetna

CVS Health Corporation reported a 6.3% increase in total revenues for the third quarter of 2024, reaching $95.4 billion.

CVS Reports Mixed Q3 Results: Revenue Beats Forecast, Earnings Decline

"Encouraged" by OakStreet's performance. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try ...

CVS Health 'encouraged' by growth of healthcare delivery assets

Expects to return to "more normal" leverage ratio over time. "Remains committed" to maintaining investment grade credit rating. Published first on ...

CVS Health says leverage ratio 4.6x at end of Q3

In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on CVS Health (CVS – Research Report), with a price ta...

Evercore ISI Keeps Their Buy Rating on CVS Health (CVS)

Says making operational changes, utilizing AI to improve services and processes. "Confident" in taking right steps to turn around the Aetna busines...

CVS Health says taking 'meaningful steps' to strengthen Aetna business

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

Health insurers climb after Trump win

ALHC

ATHM

AUDC

CELH

CLOV

ENOV

EXAS

HNDAF

IONS

IRBT

VERX

Press Releases

CVS Health supporting customers, patients, members and colleagues as Hurricane Milton approaches

Aetna shines in Star Ratings with 88 percent of Medicare Advantage members in 4-star plans or higher for 2025

Contracts

Aetna recommended for new D-SNP contract by the State of Michigan

New CVS Health® report explores ongoing transformation of community pharmacy

Aetna introduces SimplePay Health

CVS Health Appoints David Joyner President and Chief Executive Officer

CVS Health Foundation helps address barriers to care for patients with chronic diseases in Atlanta

Legal

CVS ALERT: Bragar Eagel & Squire, P.C. is Investigating CVS Health Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS

CVS Health Announces Leadership Appointments

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

空売り

CVS Health (NYSE:CVS) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル